Search PubMed⌕ Search

Biomedical subjects

Y Noguchi

Publications and source records attributed to Y Noguchi.

At least 397 records · Page 22Linked to original sources
PubMed1987

[A case of primary signet ring cell carcinoma of the breast].

A rare case of primary signet ring cell carcinoma of the breast is reported. The patient was a 54-year-old unmarried female (G 0, P 0, AB 0) with a several months' history of inflammatory reactions, such as infection, erosion, and a swelling of her entire left breast. She died of this disease in 6 months despite an operation and combined chemotherapy (CMF). Her serum CEA level had well reflected the course of her treatment. Histopathologically, a primary lesion and axillary lymph nodes were found to be filled with typical signet ring cells, whose cytoplasm showed positive staining for PAS and Alcian blue stains as well as CEA. This case, both clinically and histopathologically, displayed the peculiar characteristics of signet ring cell carcinoma, which differs from other types of breast cancer.

Adenocarcinoma, Mucinous↗
PubMed1987

[The effect of gastrectomy on serum 5-FU concentrations of patients administered UFT per os].

Ten post-total gastrectomy patients and five postsubtotal patients were administered with UFT 3 capsules per os. Then the concentrations of the serums FT-207, 5-FU and Uracil, and that of 5-FU in the lymph-nodes were measured chronologically. The concentration of serum FT-207 reached to its peak one hour after administration of the regimen for both the total and subtotal gastrectomy patients and gradually lowered. The 5-FU serum concentration, on the other hand, showed a rapid drop after reaching a peak one hour after administration of the UFT for both the post-total and subtotal gastrectomy patients. The concentration of 5-FU in the lymph nodes remained five times as high as the serum concentration after four hours for both the post-total and subtotal gastrectomy patients.

Adult↗
PubMed1987

[Biosynthesis of prostaglandin in human cervical tissue].

It is known that prostaglandin (PG)E2 and PGI2 can contribute to the ripening of the uterine cervix. To study the PG biosynthesis in cervical tissue, 14C-arachidonic acid was used to incubate the preparation of human cervical tissue obtained from pregnant women at delivery and non pregnant women at hysterectomy. Labeled PGE2 and 6-keto-PGF1 alpha (6PG), a stable metabolite of PGI2 were isolated on TLC, and the enzymatic activity was calculated from the formation of PGE2 and 6PG from arachidonic acid. The capacity to metabolize arachidonic acid to PGE2 and 6PG in cervical tissue obtained from pregnant women was 6 times higher than that from non pregnant women. Low enzymatic activity in the formation of PGE2 and 6PG were observed in cervical tissues from the patients with placental sulfatase deficiency and preterm delivery which were known to have a low estrogen environment. On the other hand, DHA-S administration to patients increased the formation of both PGE2 and 6PG. These results demonstrate that human cervical tissue possesses the ability to synthesize PGE2 and PGI2, and enzymatic activity increased during pregnancy, and was further enhanced by the administration of DHA-S. The results suggest that the steroids in the fetoplacental unit may be involved in the mechanism controlling the formation of PGs in the cervical tissue which lead the cervix to ripen at term.

6-Ketoprostaglandin F1 alpha↗
PubMed1987

[Investigation of clinical effect of flomoxef].

Flomoxef (FMOX, 6315-S) is a new antibiotic of oxacephem group with a broad antibacterial spectrum. Seven patients were treated by intravenous instillation of 1 g of FMOX twice daily. Seven-day treatment with FMOX was ineffective against chronic bronchitis caused by Escherichia coli in a patient who had received an operation for esophageal cancer 6 years previously. Seven-day treatment with FMOX was effective against acute pneumonia caused by Staphylococcus aureus in a patient with lung cancer. Nine-day treatment with FMOX was effective against pulmonary suppuration caused by Streptococcus pneumoniae in a patient with lung cancer. Six-day and 7-day treatment with FMOX were excellently or moderately effective against suspected obstructive pneumonia in 2 patients with lung cancer. Five-day and 6-day treatment with FMOX were ineffective against fever of unknown origins in 2 patients with lung cancer. Overall, FMOX was effective in 4 of the 7 patients evaluated.

Aged↗
PubMed1987

[A case of non-neoplastic pineal cyst presenting Parinaud's syndrome].

A case of non-neoplastic pineal cyst with Parinaud's syndrome is presented. A 54-year-old woman was admitted to the department of neurosurgery. Fukui Medical School on October, 1985, complaining of the paralysis of upward gaze. A computed tomography (CT) demonstrated a low density mass in the pineal region and the mass was not enhanced after the injection of contrast agent. Metrizamide CT cisternogram delineated the mass clearly. Bilateral carotid and vertebral angiograms showed no significant findings. On November 5, an operation was performed by means of an occipital transtentorial approach. A cyst filled with clear yellowish fluid was found in the pineal region. The cyst was evacuated and its wall was subtotally resected. The histological examination revealed the cystic cavity lined by fibrous astrocytes which were surrounded by normal pineal tissue. Therefore the cyst was diagnosed as a non-neoplastic pineal cyst. The postoperative course was uneventful. The paralysis of upward gaze was gradually improved. On December 27, the patient was discharged in excellent condition. Non-neoplastic small cysts which do not cause an enlargement of the pineal body are common incidental findings at autopsy, whereas large cysts which cause symptoms due to compression of the corpora quadrigemina and the production of internal hydrocephalus are rare. In this paper, non-neoplastic pineal cyst is discussed.

Brain Diseases↗
PubMed1986

Distribution of endothelial vesicles in the microvasculature of skeletal muscle and brain cortex of the rat, as demonstrated by tannic acid tracer analysis.

Ultrathin serial sectioning and labeling with tannic acid have demonstrated that most plasmalemmal vesicles of rat vascular endothelial cells are not free, but rather are conjoined in three dimensions to form racemose invaginations from the cell surfaces. To elucidate the distribution of vesicles in these microvascular endothelial cells, we have examined terminal arterioles, capillaries and post-capillary venules of rat skeletal muscle and brain cortex, using tannic acid labeling and stereological methods, and have determined the proportions of free vesicles and the vesicles of luminal and abluminal invaginations, as well as the numerical density of vesicles. In the case of capillaries, regional differences in distribution have also been studied. The ratio of free vesicles is 6-7% and is constant throughout the muscle microvasculature. The distribution (proportions and numerical densities) of vesicles in the brain and muscle microvascular endothelial cells shows regionally distinctive patterns. In rapid-frozen, freeze-substituted endothelial cells, there are almost as many fused vesicles as seen in chemically fixed cells. Therefore, aldehydes do not seem to induce membrane fusion, and the distribution of vesicles seems to be preserved by chemical fixation. The structure and function of plasmalemmal vesicles are discussed.

Animals↗
PubMed1986

Effects of cyclic nucleotides, betazole hydrochloride and acetylcholine on pepsinogen secretion from isolated rabbit gastric mucosa.

The effects of dibutyryl cyclic AMP (db-cAMP), dibutyryl cyclic GMP (db-cGMP), betazole hydrochloride (betazole) and acetylcholine (ach.) on pepsinogen secretion from isolated rabbit gastric mucosa were studied using an organ culture system. The 10(-3) M db-cAMP, but not db-cGMP of any concentration, produced a significant enhancement of pepsinogen secretion into the culture medium. In the presence of aminophylline (phosphodiesterase inhibitor), betazole stimulated pepsinogen secretion at concentrations of 10(-8), 10(-6) and 10(-4) M. The 10(-4) M betazole stimulated pepsinogen secretion most strongly (208% of control) and 10(-6) M betazole induced submaximal secretion (137% of control). Ach. stimulated pepsinogen secretion at 10(-8), 10(-6), 10(-4) and 10(-2) M. The peak secretion occurred at 10(-4) M ach. (303% of control). Betazole (with aminophylline) against a background of 10(-6) M ach. (submaximal stimulation dose), produced an intense stimulation of pepsinogen secretion at the concentrations of 10(-8), 10(-6) and 10(-4) M, and the secretion rate expressed as percent of control were 277, 350 and 329%, respectively. These responses were not considered the additive action by betazole and ach. but the potential interaction between the two agents in pepsinogen secretion. From these findings, we conclude that betazole-ach. interdependency exists in in vitro pepsinogen secretion.

Acetylcholine↗
PubMed1986

Interrelationship between pituitary and ovarian hormones in normal and neoplastic growth of mammary glands of mice.

While prolactin is a key hormone for normal and neoplastic mammary gland growth, the participation of ovarian estrogen and progesterone is essential for these processes under the normal physiological conditions. Prolactin exerts its influence directly to the glands and indirectly through its luteotropic effects by stimulation of ovarian progesterone secretion. Furthermore, the action of prolactin, whether in promoting normal growth and function or enhancing the progression of neoplastic foci, depends upon the circulating levels of other mammotropic hormones as well as the level of prolactin itself. Presence of estrogen and prolactin is essential for manifestation of progesterone effects on mammary gland growth. Estrogen acts on the mammary glands directly by modulating mammary cell responsiveness to prolactin and indirectly by stimulating pituitary prolactin secretion. While data have been accumulated on the effects of growth hormone on mammary gland growth, the significance of these findings is still unknown. Neoplastic potential of mammary cells is largely dependent upon the susceptibility of the cells to mammotropic hormones.

Animals↗
PubMed1986

[Combination chemotherapy and radiotherapy in small cell carcinoma of the lung].

Thirty-nine patients with small cell carcinoma of the lung were treated sequentially with induction chemotherapy, radiotherapy and then maintenance chemotherapy. Induction chemotherapy consisted of two regimens, cyclophosphamide, vincristine, methotrexate (COM) and adriamycin, ACNU, vindecine (ANV) given by randomization. Radiotherapy was given for patients with limited disease (LD) as a rule. After radiotherapy the drugs used for maintenance chemotherapy were alternated and reduced in dose. Eighteen patients were treated with a COM-ANV sequential combination and sixteen patients were treated with an ANV-COM combination. Thirteen patients had limited disease (LD) and eleven patients had extensive disease (ED). Of 12 patients with LD treated with COM-ANV therapy, 9 patients (75%) responded with 3 (25%) complete responses. Of 11 patients with LD treated with ANV-COM therapy, 9 patients (81.8%) responded to the therapy. According to disease extent, response rate was 82.6% for LD and 54.5% for ED. The median survival times were 9 months for patients with COM-ANV therapy and 12 months for those with ANV-COM therapy. Also, the median survival time was 15 months for LD patients and 5 months for ED patients. Major toxicities in ANV therapy were anorexia, nausea, and myelosuppression, and were more frequent than with COM therapy. These results showed no clear evidence of superiority in either the COM-AMV or ANV-COM regimen.

Adult↗
PubMed1986

[Combination chemotherapy with etoposide, mitomycin C, and cyclophosphamide in advanced non-small cell lung cancer].

Forty-three patients with advanced non-small cell lung cancer were treated with a combination chemotherapy regimen comprising etoposide 100 mg/m2 p.o. days 1-5, mitomycin C 10 mg/m2 i.v. day 1 and cyclophosphamide 500 mg/m2 i.v. day 1, every 4 weeks. The median age was 61, and the median initial PS-2. Fourteen patients had received prior therapy. The response rates in previously untreated patients were 25% (5/20) for adenocarcinoma, 0% (0/4) for squamous cell carcinoma, 0% (0/3) for large cell carcinoma, and 18.5% (5/27) for all patients. There were no responders among the pretreated patients. The median survival time was 7 months for previously untreated patients, 4 months for pretreated patients and 6 months for all patients. Patients with adenocarcinoma survived significantly longer (8 months) than those with squamous cell carcinoma (4 months) and large cell carcinoma (3 months). Toxicity consisted of leukopenia (74%), anemia (74%), nausea or vomiting (55%) and alopecia (94%).

Adenocarcinoma↗